NOVO.B.DK

247.85

-3.71%↓

GMAB.DK

1,731.5

-2.37%↓

COLO.B.DK

429.2

-1.27%↓

ZEAL.DK

301.4

-4.35%↓

AMBUB.DK

69.5

-0.43%↓

NOVO.B.DK

247.85

-3.71%↓

GMAB.DK

1,731.5

-2.37%↓

COLO.B.DK

429.2

-1.27%↓

ZEAL.DK

301.4

-4.35%↓

AMBUB.DK

69.5

-0.43%↓

NOVO.B.DK

247.85

-3.71%↓

GMAB.DK

1,731.5

-2.37%↓

COLO.B.DK

429.2

-1.27%↓

ZEAL.DK

301.4

-4.35%↓

AMBUB.DK

69.5

-0.43%↓

NOVO.B.DK

247.85

-3.71%↓

GMAB.DK

1,731.5

-2.37%↓

COLO.B.DK

429.2

-1.27%↓

ZEAL.DK

301.4

-4.35%↓

AMBUB.DK

69.5

-0.43%↓

NOVO.B.DK

247.85

-3.71%↓

GMAB.DK

1,731.5

-2.37%↓

COLO.B.DK

429.2

-1.27%↓

ZEAL.DK

301.4

-4.35%↓

AMBUB.DK

69.5

-0.43%↓

Search

H Lundbeck A-S

Gesloten

43.08 -0.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.76

Max

43.76

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.7B

-27M

Verkoop

-465M

5.8B

K/W

Sectorgemiddelde

12.485

63.808

EPS

0.94

Dividendrendement

2.85

Winstmarge

-0.464

Werknemers

5,039

EBITDA

130M

1.8B

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.85%

2.38%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-546M

40B

Vorige openingsprijs

43.68

Vorige sluitingsprijs

43.08

H Lundbeck A-S Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 apr 2026, 23:49 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand 1Q Inflation Higher Than Expected

20 apr 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 apr 2026, 22:53 UTC

Belangrijke Marktbewegers

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 apr 2026, 23:44 UTC

Marktinformatie

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 apr 2026, 23:39 UTC

Marktinformatie

Rio Tinto Posts Strong Start to Year -- Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 apr 2026, 23:09 UTC

Marktinformatie

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 apr 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:26 UTC

Acquisities, Fusies, Overnames

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Aims for Acquisition to Be Completed by End-2026

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Says Acquisition Would Be for A$175 Million

20 apr 2026, 22:24 UTC

Acquisities, Fusies, Overnames

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 apr 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 apr 2026, 21:38 UTC

Marktinformatie

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 apr 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 apr 2026, 21:24 UTC

Marktinformatie

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 apr 2026, 21:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 apr 2026, 21:13 UTC

Winsten

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 apr 2026, 21:10 UTC

Winsten

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 apr 2026, 21:09 UTC

Winsten

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 apr 2026, 21:08 UTC

Winsten

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 apr 2026, 21:07 UTC

Winsten

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 apr 2026, 21:05 UTC

Winsten

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 apr 2026, 21:05 UTC

Winsten

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Peer Vergelijking

Prijswijziging

H Lundbeck A-S Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat